Literature DB >> 28398959

Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya.

Seth C Inzaule1, Raph L Hamers, Irene Mukui, Kennedy Were, Prestone Owiti, Daniel Kwaro, Tobias F Rinke de Wit, Clement Zeh.   

Abstract

: We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of patients harbouring intermediate-to-high-level resistance was 27% for lopinavir-ritonavir, 24% for atazanavir-ritonavir and 7% for darunavir-ritonavir, and 25% had complete loss of activity to all available first and second-line drugs. Overall, one in four patients failing second-line ART have completely exhausted available antiretrovirals in Kenya, highlighting the need for increased access to third-line drugs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28398959     DOI: 10.1097/QAD.0000000000001500

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  9 in total

Review 1.  Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.

Authors:  Carole L Wallis; Catherine Godfrey; Joseph E Fitzgibbon; John W Mellors
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

2.  Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Authors:  Robert W Shafer
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

3.  HIV-1 Drug Resistance and Virologic Outcomes Among Tanzanian Youth Living With HIV.

Authors:  Dorothy E Dow; Aisa M Shayo; Coleen K Cunningham; Blandina T Mmbaga
Journal:  Pediatr Infect Dis J       Date:  2019-06       Impact factor: 2.129

4.  Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Authors:  Beatriz Grinsztejn; Michael D Hughes; Justin Ritz; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Robert Gross; Catherine Godfrey; Sandra W Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Faesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Anchalee Avihingsanon; Breno R Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T Schooley; John W Mellors; Carole L Wallis; Ann C Collier
Journal:  Lancet HIV       Date:  2019-07-29       Impact factor: 12.767

5.  HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.

Authors:  Cleophas Chimbetete; David Katzenstein; Tinei Shamu; Adrian Spoerri; Janne Estill; Matthias Egger; Olivia Keiser
Journal:  Open Forum Infect Dis       Date:  2018-02-02       Impact factor: 3.835

6.  A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy.

Authors:  Karen Cohen; Annemie Stewart; Andre P Kengne; Rory Leisegang; Marla Coetsee; Shavani Maharaj; Liezl Dunn; Michael Hislop; Gert van Zyl; Graeme Meintjes; Gary Maartens
Journal:  J Acquir Immune Defic Syndr       Date:  2019-03-01       Impact factor: 3.731

7.  Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.

Authors:  Adetayo Emmanuel Obasa; Anoop T Ambikan; Soham Gupta; Ujjwal Neogi; Graeme Brendon Jacobs
Journal:  BMC Infect Dis       Date:  2021-02-25       Impact factor: 3.090

8.  Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis.

Authors:  Alexander J Stockdale; Matthew J Saunders; Mark A Boyd; Laura J Bonnett; Victoria Johnston; Gilles Wandeler; Annelot F Schoffelen; Laura Ciaffi; Kristen Stafford; Ann C Collier; Nicholas I Paton; Anna Maria Geretti
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079

9.  Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART.

Authors:  Lucas E Hermans; Kim Steegen; Rob Ter Heine; Rob Schuurman; Hugo A Tempelman; Robert Moraba; Erik van Maarseveen; Monique Nijhuis; Taryn Pillay; Derryn Legg-E'Silva; Tracy Snyman; Jonathan M Schapiro; David M Burger; Sergio Carmona; Annemarie Mj Wensing
Journal:  J Int AIDS Soc       Date:  2020-06       Impact factor: 5.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.